Please Scroll Down to See Forums Below HiFidelity
New member
guys, if you are getting tested SPECIFICALLY for juice, is Gh or Insulin detectable? I am arguing with a nerd over this, and I don't think it is detectable. Am I right?
Last edited:
GH and Slin..... Drug Test Question
- Thread starter HiFidelity
- Start date
HiFidelity
New member
anyone?
anyone know?
anyone know?
J
Juice Authority
Guest
Nope, not yet anyway.
C
Citruscide
Guest
I don't think it is detectable by testing... but to the naked eye.. it might be. 
C-ditty
C-ditty
Both GH and slin are not detectable in a urine test. GH is detectable in a blood test. You might find the following interesting:
"The detection of growth hormone abuse in sport
P. Sonksen
The GH-2000 Project (Biomed 2 Contract number BMH4 CT950678), St Thomas’s Hospital London, UK
--------------------------------------------------------------------------------
Growth hormone is probably the most anabolic substance yet discovered. It acts directly to stimulate protein synthesis and simultaneously mobilises fat. It acts through a mechanism that is distinct from that of anabolic steroids and its action is complementary to that of testosterone. In adults, growth hormone is probably the most important substance responsible for the development and maintenance of lean body mass. In its absence lean body mass falls and fat accumulates.
Growth hormone has been available in unlimited amounts since the late 1980’s and evidence has accumulated showing it to be increasingly abused in sport. The synthetic recombinant growth hormone (rhGH) is the 22k isomer identical to the naturally occurring substance. There are no validated methods of detecting rhGH abuse. Athletes can therefore abuse one of the most anabolic agents known with no risk of detection.
GH-2000 was a research project funded by the European Union under their BIOMED 2 research programme with matching funds from the IOC. It’s objective was to develop a methodology for detecting rhGH abuse in time for the Sydney Olympic Games. It ran between January 1996 and 1999. It brought together leading endocrinologists from four European countries (Sweden, Denmark, Italy & UK) with the two European rhGH manufacturers (Novo Nordisk & Pharmacia Upjohn) and the IOC Medical Commission. More than a thousand volunteer elite athletes from around the world participated in the project. The GH-2000 team submitted their Final Report to the European Union and the IOC in January 1999. GH-2000 succeeded in developing a method of detecting rhGH abuse with reasonable sensitivity and very high specificity with a ‘false positive’ rate as low as 1:10,000.
Detection of rhGH abuse relies on two methods:
Detection of the 22k isomer of GH in the absence of the naturally occurring 20k isomer
Detection of one or more ‘indirect markers’ of rhGH administration in concentrations higher than is possible within normal physiological variance
The former method is particularly useful in detectingrhGH administration within the last 24h while the latter can detect the use of rhGH as long ago as 14 days before the test. Both methods rely on blood rather than urine tests.
GH-200 has thus ‘cracked the nut’ and has shown the detection of growth hormone abuse to be possible. Both tests have very high specificity and adequate sensitivity but before being implemented need further validation to show (amongst other things) that results in other ethnic groups are comparable to those found in the predominantly white Europeans who took part in the first Phase of GH-2000. This new programme of work will be submitted to the IOC for consideration in their recently launched $2 Million research initiative.
Title: GH-2000 A Methodology for the Detection of Doping with Growth Hormone & Related Substances
Contract Number: BMH4 CT950678 Official Contractual period: 1st January 1996-31st January 1999
Co-ordinator: Prof. Peter Sönksen, U.M.D.S, St Thomas’ Hospital, London, UK
Participants:
Prof. B.A. Bengtsson, Sahlgrenska University Hospital, Goteborg, Sweden
Prof. J.S. Christiansen, Aarhus University Hospital, Aarhus, Denmark
Prof. L. Sacca, University Federico II, Naples, Italy
Prince Alexander De Merode, IOC Medical Commission, Lausanne, Switzerland
Dr Anne-Marie Kappelgaard, Novo Nordisk, Gentofte, Denmark
Dr Linda Fryklund, Pharmacia Upjohn, Stockholm Sweden
Drs Laurent Rivier & Matial Saugy, IOC Laboratory, Lausanne, Switzerland
Prof. Philip Brown, Drs Eryl Bassett & Mike Kenward, University of Kent, UK
Dr Ross Cuneo, Ms Jennifer Wallace, Princess Alexandra Hospital, Brisbane, Australia
Prof. Rob Baxter, Royal North Shore Hospital, St Leonards, Queensland, Australia
Dr Christian Strasburger, Innenstadt Hospital of Ludwig-Maximilans University, Munich, Germany "
You can get the full paper at:
http://journals.endocrinology.org/joe/170/0013/1700013.pdf
"The detection of growth hormone abuse in sport
P. Sonksen
The GH-2000 Project (Biomed 2 Contract number BMH4 CT950678), St Thomas’s Hospital London, UK
--------------------------------------------------------------------------------
Growth hormone is probably the most anabolic substance yet discovered. It acts directly to stimulate protein synthesis and simultaneously mobilises fat. It acts through a mechanism that is distinct from that of anabolic steroids and its action is complementary to that of testosterone. In adults, growth hormone is probably the most important substance responsible for the development and maintenance of lean body mass. In its absence lean body mass falls and fat accumulates.
Growth hormone has been available in unlimited amounts since the late 1980’s and evidence has accumulated showing it to be increasingly abused in sport. The synthetic recombinant growth hormone (rhGH) is the 22k isomer identical to the naturally occurring substance. There are no validated methods of detecting rhGH abuse. Athletes can therefore abuse one of the most anabolic agents known with no risk of detection.
GH-2000 was a research project funded by the European Union under their BIOMED 2 research programme with matching funds from the IOC. It’s objective was to develop a methodology for detecting rhGH abuse in time for the Sydney Olympic Games. It ran between January 1996 and 1999. It brought together leading endocrinologists from four European countries (Sweden, Denmark, Italy & UK) with the two European rhGH manufacturers (Novo Nordisk & Pharmacia Upjohn) and the IOC Medical Commission. More than a thousand volunteer elite athletes from around the world participated in the project. The GH-2000 team submitted their Final Report to the European Union and the IOC in January 1999. GH-2000 succeeded in developing a method of detecting rhGH abuse with reasonable sensitivity and very high specificity with a ‘false positive’ rate as low as 1:10,000.
Detection of rhGH abuse relies on two methods:
Detection of the 22k isomer of GH in the absence of the naturally occurring 20k isomer
Detection of one or more ‘indirect markers’ of rhGH administration in concentrations higher than is possible within normal physiological variance
The former method is particularly useful in detectingrhGH administration within the last 24h while the latter can detect the use of rhGH as long ago as 14 days before the test. Both methods rely on blood rather than urine tests.
GH-200 has thus ‘cracked the nut’ and has shown the detection of growth hormone abuse to be possible. Both tests have very high specificity and adequate sensitivity but before being implemented need further validation to show (amongst other things) that results in other ethnic groups are comparable to those found in the predominantly white Europeans who took part in the first Phase of GH-2000. This new programme of work will be submitted to the IOC for consideration in their recently launched $2 Million research initiative.
Title: GH-2000 A Methodology for the Detection of Doping with Growth Hormone & Related Substances
Contract Number: BMH4 CT950678 Official Contractual period: 1st January 1996-31st January 1999
Co-ordinator: Prof. Peter Sönksen, U.M.D.S, St Thomas’ Hospital, London, UK
Participants:
Prof. B.A. Bengtsson, Sahlgrenska University Hospital, Goteborg, Sweden
Prof. J.S. Christiansen, Aarhus University Hospital, Aarhus, Denmark
Prof. L. Sacca, University Federico II, Naples, Italy
Prince Alexander De Merode, IOC Medical Commission, Lausanne, Switzerland
Dr Anne-Marie Kappelgaard, Novo Nordisk, Gentofte, Denmark
Dr Linda Fryklund, Pharmacia Upjohn, Stockholm Sweden
Drs Laurent Rivier & Matial Saugy, IOC Laboratory, Lausanne, Switzerland
Prof. Philip Brown, Drs Eryl Bassett & Mike Kenward, University of Kent, UK
Dr Ross Cuneo, Ms Jennifer Wallace, Princess Alexandra Hospital, Brisbane, Australia
Prof. Rob Baxter, Royal North Shore Hospital, St Leonards, Queensland, Australia
Dr Christian Strasburger, Innenstadt Hospital of Ludwig-Maximilans University, Munich, Germany "
You can get the full paper at:
http://journals.endocrinology.org/joe/170/0013/1700013.pdf
It takes a very sophisticated test to detect GH. The study above is one method. The Japanese use a blood test that detects elevated levels of IGF-1 and bound insulin like growth factors. The IOC has not implemented any method as yet, which is why olympic athletics are awash in exoGH use.
So the ordinary joe sure isn't gonna get caught.
Note in the above test, it can detect GH use 14 days back. Athletes will know when to cycle off, now won't they?
So the ordinary joe sure isn't gonna get caught.
Note in the above test, it can detect GH use 14 days back. Athletes will know when to cycle off, now won't they?
